taranabant
Sign in to saveTaranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was developed by Merck & Co.
Chemical data
- Formula
- C27H25ClF3N3O2
- Molecular weight
- 516 g/mol
- IUPAC name
- N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]propanamide
via PubChem
Article
2 sectionsContents
- See also
- References
{{Drugbox | Watchedfields = changed | verifiedrevid = 448081332 | IUPAC_name = N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide | image = Taranabant.svg | image_class = skin-invert-image | alt = Skeletal formula of taranabant | width = 250 | image2 = Taranabant 3D spacefill.png | image_class2 = bg-transparent | alt2 = Space-filling model of the taranabant molecule
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational (failed) | routes_of_administration = Oral